Project Grant R01HL188510
Award Date 8/25/26
Completion Date 6/30/30
Dollars Obligated $818K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $1,657,587 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect molecular pathways controlling human pacemaker development. The recipient will conduct research aimed at identifying key transcriptional regulators of sinoatrial node (SAN) differentiation using CRISPR interference and activation in human pluripotent stem cells, then validate findings in...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $768,414 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct multi-omic profiling research examining the relationship between idiopathic pulmonary fibrosis and cardiovascular disease. The research identifies shared molecular mechanisms linking pulmonary fibrosis and cardiovascular disease through blood-based and tissue analysis. The project defines shared...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $704,851 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance tissue characterization methods for prognostication and therapeutic response prediction in functional tricuspid regurgitation. The project leverages newly developed CMR techniques optimized for the thin-walled right ventricle, including high-resolution 3D navigator late...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Cornell University $734,475 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanobiological regulation of ventricular maturation. The research will test the hypothesis that local mechanical stress operates a Piezo-Notch-YAP mechanobiological switch governing temporal compact and trabecular ventricular wall growth versus structural maturation dynamics. The...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $3.095 million on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of genetic variation's role in congenital heart disease causality and outcomes. The award funds a program project grant structured around four synergistic research projects supported by administrative and computational cores. Project 1 deepens understanding of genetic causality of...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $218,728 on March 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop computational and experimental methods for studying noncoding RNAs in hematopoiesis. The recipient will develop a computational pipeline to process and analyze single-cell total RNA sequencing (scTRS) data, a method that captures modified and non-polyadenylated noncoding RNAs—including long...
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $816,853 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 14, 2026, to investigate the role of endothelial ceramides in coronary atherosclerosis development and progression. The research tests the hypothesis that very long chain ceramides protect against coronary atherosclerosis by preserving endothelial cell resilience to atherogenic stressors through KLF2 expression....
- The National Heart Lung and Blood Institute awarded Weill Medical College of Cornell University $936,356 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 15, 2026, for the PE-TRACT Extend Study, a prospective cohort investigation of chronic thromboembolic disease following intermediate-risk pulmonary embolism treatment. The study extends the NHLBI-funded PE-TRACT randomized trial of catheter-directed therapy for acute PE by following the parent study population beyond the...